At TCT 2025, Dr Nadira Hamid (Minneapolis Heart Institute, US) and Dr. Rahul P. Sharma (Stanford University, US) review the late-breaking trial data shaping the future of structural heart disease. The discussion highlights real-world results from TRISCEND and TRILUMINATE in tricuspid disease, 7-year PARTNER 3 durability outcomes in TAVR, national prevalence insights from the PREVUE-VALVE study, and new frontiers in mitral intervention with SUMMIT MAC. Together, they examine what the evidence means for safety, durability, patient selection, and clinical adoption. 01:05 – Tricuspid Therapies Late-breaking data from Triluminate (TriClip) and Tricend/Evoke: real-world outcomes, bleeding reduction, pacemaker trends, and patient selection. 06:40 – Aortic Valve Durability PARTNER 7-year outcomes: TAVR vs. SAVR, valve performance over time, implications for younger/lower-risk patients, and evolving device technology. 12:55 – Valvular Disease Prevalence Insights from the PREVUE-VALVE: first nationwide prevalence data, under-treatment of severe disease, and role of AI in early detection. 17:30 – Mitral Valve Advances Landmark trials: SUMMIT Trial (MAC population) and first-in-human Sapien M3 transseptal TMVR. Key outcomes, screen failure rates, and implications for clinical adoption. 24:50 – Future of Structural Heart Interventions Patient-first approach, expanding treatment options, and importance of durability and early diagnosis. For more content from TCT 2025 head to the Late-breaking Science Video Collection. Editor: Mirjam Boros Videographer: Tom Green and Dan Brent Support: This is an independent video produced by Radcliffe Cardiology.